Watchdog Report Reaffirms Concerns With Fail First
BIOtech Now Brian Newell A new report by the Office of Inspector General at the U.S. Department of Health and Human Services […]
Category: News
2018 BIO Investor Forum Wraps Up
BIOtech Now Theresa Brady As the stock market continued its volatile swings this week, investors at the BIO Investor Forum—which wrapped up […]
World AMR Congress Keynote Panel to Explore Making “Pull” Incentives a Reality
BIOtech Now BIOtechNOW Editor Here’s a statistic you might not have known: an estimated 700,000 people die each year due to the […]
Drug Importation: Dangerous for Patients, Consumers, and American Communities
BIOtech Now Andrew Segerman Writing for The Hill, Steve Forbes, Forbes Media Chairman and Editor in Chief, delivered a simple message to […]
To Ensure History Does Not Repeat Itself, Get a Flu Shot
BIOtech Now Andrew Segerman The Centers for Disease Control and Prevention (CDC) is out with shocking new data: an estimated 80,000 Americans […]
Trump’s Drug Pricing Blueprint to be Explored at Upcoming Summit
BIOtech Now Theresa Brady In just a few short weeks, BIO will host its annual Patient and Health Advocacy Summit which brings […]
Digital Health Innovation to be Spotlighted at the BIO Investor Forum
BIOtech Now Jessica Torres Is your company trying to expand into “digiceuticals” or digital therapeutics? Are you looking to meet with investors […]
UN Proposals to Weaken IP Will Not Benefit Patients
BIOtech Now George Goodno Next week the 73rd session of the United Nations General Assembly (UNGA) will convene in New York City. […]
The Role – and Value – of Public-Private Partnerships in Preparedness
BIOtech Now BIOtechNOW Editor Nearly twelve years ago, members of the biopharmaceutical supply chain, including BIO, came together in the aftermath of […]
Medical Research from Mars Can Fail Patients from Venus
BIOtech Now Jim Greenwood Historically, federal dollars inadvertently flowed to medical research with a disproportionate focus on men’s health. There are several […]
Pathbreaking Biotech Investor—Dr. Beth Seidenberg—to Speak at #BIF18
BIOtech Now Theresa Brady The rapid pace of scientific discovery, FDA approvals, commercialization of medicines held long in pipelines, and numerous IPOs […]
Bloomberg Exposes How Drug Cost Middlemen “Rake in Millions”
BIOtech Now Andrew Segerman Bloomberg has authored an investigative piece exposing drug cost middlemen, better known as pharmacy benefit managers (PBMs), for […]
Greenwood Highlights Role of Innovation in Solving Opioid Crisis
BIOtech Now Andrew Segerman The numbers are staggering. The opioid epidemic is costing our nation more than $500 billion annually in health and social […]
The Patient Perspective-Valuable for Drug Development
BIOtech Now Theresa Brady Congress, the Food and Drug Administration (FDA), drug developers, researchers and patient groups have all recognized the contribution […]
Healthcare AI is Booming
BIOtech Now Jeremy Isenberg Emerging technologies are disrupting the healthcare system as we know it—none more so than artificial intelligence (AI), which […]
National Immunization Awareness Month is Timely Reminder of Modern Marvel of Vaccines
BIOtech Now Phyllis Arthur August marks National Immunization Awareness Month – a time to take inventory on where we stand, and recognize […]
Vaccine Video Series Aims to Educate on the Benefits of Immunization
BIOtech Now Andrew Segerman National Immunization Awareness Month might be coming to a close, but it’s important to continue helping people understand […]
Report: Patients More Likely to Skip Therapy as Out-of-Pocket Costs Rise
BIOtech Now Andrew Segerman IQVIA — a nonpartisan health care research firm — is out with troubling new data showing a direct […]
PBS NewsHour: Why a Patient Paid a $285 Copay for a $40 Drug
BIOtech Now Andrew Segerman A featured story by PBS NewsHour reaffirms that insurance companies and drug cost middlemen determine what patients pay […]
Senate Has the Power to Get Miracle Medications to Opioid Addicts
BIOtech Now Jim Greenwood BIO President and CEO Jim Greenwood posted the following op-ed on Linked-In today, making the case for the […]